Vertex eyes type 1 diabetes cure with biotech acquisition - PMLiVE
Vertex buys developer of preclinical cell therapy for Type 1 diabetes for $950M - MedCity News
JDRF Report: Vertex Has a New Horizon: Curing Type 1 Diabetes
Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff | The Motley Fool
Vertex – type 1 diabetes vs stem cell therapy - The Boar
Vertex to buy Semma Therapeutics for $950m in cash
Felicia Pagliuca en LinkedIn: Type 1 diabetes is a significant burden on individuals, on families, on…
Vertex: Trial of New Type 1 Diabetes Cell Therapy Put on Hold - DSM
Vertex Releases New Data on Potential Cure for Type 1 Diabetes
Vertex Releases New Data on Potential Cure for Type 1 Diabetes
Modeling Type 1 Diabetes In Vitro Using Human Pluripotent Stem Cells - ScienceDirect
JDRF Canada - Breaking News: Vertex Pharmaceuticals announced they acquired ViaCyte for $320 million in cash to help speed up the development of VX-880, Vertex's stem cell-derived therapy for people with type
Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes - PMLiVE
Vertex Moves Full Steam Ahead on Type 1 Diabetes Drug Trial With FDA's OK | BioSpace
Vertex snaps up diabetes stem cell rival | Nature Biotechnology
Vertex Forward: Diving into type 1 diabetes | Vertex
FDA suspends early study of Vertex stem-cell therapy for type 1 diabetes
Type 1 Diabetes Cures in Spotlight with Vertex Deal
Vertex reports positive results for first patient in Type 1 diabetes trial - The Boston Globe
ViaCyte Acquisition Can Accelerate Vertex's Ongoing Type 1 Diabetes Programs
Vertex: New Stem Cell Based Type 1 Diabetes Treatment Shown Effective in First Patient - DSM
FDA fast tracks type 1 diabetes cell therapy from Vertex | Pharmaphorum
Vertex's Stem Cell-Based Type 1 Diabetes Therapy To Enter Human Trial Stage | The Healthcare Technology Report.
The First Man CURED of Type 1 Diabetes | VX-880 - YouTube
Why stem cells may be the answer to curing Type 1 diabetes
Vertex builds up pipeline of type 1 diabetes cell therapies with $320M buyout - MedCity News
